Is It Time To Reconsider UiPath (PATH) After Its Recent Share Price Weakness?

  • Wondering whether UiPath at US$10.61 still offers value or if the easy gains are gone? This article breaks down what the current price may be implying about the stock.
  • The share price has moved 2.1% over the last 7 days, while the year-to-date return sits at a 33.2% decline, with a 2.2% return over the past year and much weaker 3-year and 5-year performance.
  • Recent coverage around UiPath has focused on how automation and AI tools are being adopted across industries and how that shapes expectations for software providers, as well as how companies in this space are balancing growth investments with cost control. This context helps frame why the market can quickly adjust expectations for a stock like UiPath as sentiment around automation demand and software budgets shifts.
  • UiPath currently has a value score of 5 out of 6 based on six separate valuation checks. The next sections will walk through those methods in more detail and then finish with a broader way to think about what valuation really means for you as a shareholder.

Find out why UiPath's 2.2% return over the last year is lagging behind its peers.

Advertisement

Approach 1: UiPath Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business could be worth today by projecting its future cash flows and discounting them back to a present value. It is essentially asking what those future dollars are worth in your hands right now.

For UiPath, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow stands at about $355.9 million. Analysts and model estimates project free cash flow of $510.2 million by 2029, with further projections extended out to 2035 and then discounted back using the DCF framework. All cash flows here are considered in US dollars.

On this basis, the DCF model arrives at an estimated intrinsic value of about $17.57 per share. Compared with the current share price of $10.61, this implies a 39.6% discount. This suggests that UiPath may be trading below this model’s estimate of its underlying cash flow value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests UiPath is undervalued by 39.6%. Track this in your watchlist or portfolio, or discover 60 more high quality undervalued stocks.

PATH Discounted Cash Flow as at Apr 2026
PATH Discounted Cash Flow as at Apr 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for UiPath.

Approach 2: UiPath Price vs Earnings

For profitable companies, the P/E ratio is a useful way to link what you pay for a share to the earnings that each share represents. It gives you a quick sense of how many years of current earnings the market is effectively pricing in.

What counts as a reasonable P/E depends on how quickly earnings are expected to grow and how risky those earnings are. Higher expected growth or lower perceived risk can support a higher multiple, while slower growth or higher risk usually calls for a lower one.

UiPath currently trades on a P/E of 19.7x. That is below the Software industry average of 29.7x and below the peer group average of 26.8x. Simply Wall St’s Fair Ratio for UiPath is 18.4x, which is a proprietary estimate of what a balanced P/E might look like once factors such as earnings growth, profit margins, size and risk profile are taken into account.

The Fair Ratio offers a more tailored anchor than simple peer or industry comparisons because it adjusts for UiPath’s own characteristics instead of assuming that all Software names should trade on similar multiples.

Compared with this Fair Ratio, UiPath’s actual P/E of 19.7x is slightly higher, which points to the stock being overvalued on this measure.

Result: OVERVALUED

NYSE:PATH P/E Ratio as at Apr 2026
NYSE:PATH P/E Ratio as at Apr 2026

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your UiPath Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives on Simply Wall St give you a clear story behind your numbers by tying your view of UiPath’s future revenue, earnings and margins to a forecast, a fair value and then a simple comparison with today’s price. Because these Narratives live on the Community page and update automatically when new news or earnings arrive, you can see, for example, one UiPath Narrative pointing to a fair value of about US$21.54 and another closer to US$13.81 or even US$17.00, which helps you decide whether the current price looks high or low relative to the story you find most convincing.

Do you think there's more to the story for UiPath? Head over to our Community to see what others are saying!

NYSE:PATH 1-Year Stock Price Chart
NYSE:PATH 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NYSE:PATH

UiPath

Provides an automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally.

Flawless balance sheet and undervalued.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1155.3% undervalued
50 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7719.9% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9217.2% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$1907.4% undervalued
24 users have followed this narrative
0 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

AZ
PRG logo
aziz_22khi on PRG Holdings Berhad ·

WHERE DID THE SIX MILLION SHARES GO? THE PRG OWNERSHIP TRAIL INVESTORS CANNOT IGNORE

Fair Value:RM 0.4477.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BR
Brunhilde_Wagner
CPRT logo
Brunhilde_Wagner on Copart ·

Compounder to Cash Generator in Real Time

Fair Value:US$2710.3% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.9% undervalued
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.3% undervalued
85 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28029.8% undervalued
193 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.7% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0
AN
CSMG3 logo
andre_k1tsg on Companhia de Saneamento de Minas Gerais ·

Gostei

0
|
0